OTLK FY2026 EPS Decreased by Brookline Capital Management

Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - Equities researchers at Brookline Capital Management decreased their FY2026 earnings estimates for Outlook Therapeutics in a research report issued to clients and investors on Tuesday, May 27th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings of $0.50 per share for the year, down from their prior forecast of $0.54. The consensus estimate for Outlook Therapeutics' current full-year earnings is ($2.27) per share.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.15.

A number of other research firms have also recently commented on OTLK. Chardan Capital reiterated a "neutral" rating and set a $3.00 price objective on shares of Outlook Therapeutics in a research report on Tuesday, February 18th. HC Wainwright reduced their price target on shares of Outlook Therapeutics from $30.00 to $3.00 and set a "buy" rating for the company in a research report on Tuesday, February 18th. Guggenheim reiterated a "buy" rating on shares of Outlook Therapeutics in a research note on Tuesday, May 20th. Finally, Ascendiant Capital Markets dropped their price objective on shares of Outlook Therapeutics from $33.00 to $24.00 and set a "buy" rating on the stock in a report on Monday, February 24th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $10.20.

Outlook Therapeutics Stock Performance

Shares of NASDAQ OTLK traded down $0.08 during midday trading on Thursday, hitting $1.77. 1,298,207 shares of the stock traded hands, compared to its average volume of 776,470. The firm has a market capitalization of $59.25 million, a P/E ratio of -0.24 and a beta of 0.39. Outlook Therapeutics has a one year low of $0.87 and a one year high of $9.25. The firm has a 50-day moving average of $1.48 and a two-hundred day moving average of $1.85.

Hedge Funds Weigh In On Outlook Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. raised its stake in shares of Outlook Therapeutics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company's stock worth $126,000 after buying an additional 44,063 shares during the period. AQR Capital Management LLC increased its holdings in Outlook Therapeutics by 42.7% in the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company's stock worth $103,000 after acquiring an additional 25,351 shares in the last quarter. Jane Street Group LLC raised its stake in Outlook Therapeutics by 133.9% during the 4th quarter. Jane Street Group LLC now owns 26,218 shares of the company's stock worth $50,000 after acquiring an additional 15,008 shares during the period. Scotia Capital Inc. raised its stake in Outlook Therapeutics by 124.4% during the 4th quarter. Scotia Capital Inc. now owns 73,989 shares of the company's stock worth $140,000 after acquiring an additional 41,023 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in Outlook Therapeutics during the fourth quarter valued at approximately $246,000. 11.20% of the stock is currently owned by hedge funds and other institutional investors.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.